Researchers report early success with an antibody therapy called linvoseltamab for the blood cancer multiple myeloma. The phase 2 trial was led by Dickran Kazandjian with C. Ola Landgren. The study enrolled 25 patients at Sylvester and its satellite sites.
Eighteen participants completed up to six cycles of linvoseltamab. Doctors used very sensitive bone marrow tests that can find one cancer cell in a million normal cells. None of the 18 who finished treatment had detectable disease on those tests. Some patients had side effects such as low white blood cells and upper respiratory infections, but investigators described the safety as acceptable. The team will expand enrollment to 50 people and conduct larger studies to learn more.
Difficult words
- antibody — a protein made by the immune system
- therapy — treatment to help a medical problem
- multiple myeloma — a cancer of plasma cells in blood
- trial — a medical study testing a new treatmentphase 2 trial
- enroll — to put people into a studyenrolled
- detectable — able to be found by a test
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Related articles
Who decides tropical medicine research?
A new analysis finds most journal editors in tropical medicine come from wealthy countries. The study links editorial imbalance to funding gaps and calls for more diversity, local training and fairer partnerships.
Why African Men Should Get Tested for Prostate Cancer
Prostate cancer is a major health issue for African men. Early testing can help improve survival rates.
Climate threat to banana exports
Rising temperatures and heat waves are putting banana production and exports at risk in Latin America. A study warns suitable growing areas could fall sharply by 2080, and farmers and scientists are testing ways to adapt.
Seeing Uncertainty as an Opportunity
Researchers at ETH Zurich tested a short presentation that asked people to see uncertainty as an opportunity. The experiment in Germany (Dec 2024–Mar 2025) changed attitudes to diversity, social change and voting for AfD.
Time of day may affect glioblastoma chemotherapy
New research finds that daily cycles of the DNA repair enzyme MGMT change during the day and may alter how glioblastoma responds to temozolomide. Biopsy timing and chronotherapy testing are next steps.
Territory fights help Ngogo chimpanzees have more babies
Study of Ngogo chimpanzees in Uganda finds that killing neighbouring groups and expanding territory led to more births and much better infant survival in the three years after expansion.